MBX Biosciences
MBX
49.55
-3.86
-7.23%
MBX Biosciences
US · MBX
#2567 by market cap
Listed 2024
49.55
-3.86
-7.23%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 13 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.3 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 117.26% -0.30pp
- Institutions
- 221 +13
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund57.72%
VC/PE Fund35.97%
Hedge Fund20.40%
Individual/Insider2.64%
Public Company2.32%
Insurance Company0.33%
Government Pension Fund0.25%
Private Company0.17%
Top holders as of 2026-09-30
FMR
14.84% · 7.37M sh
Frazier Life Sciences Management, LP
13.40% · 6.65M sh
Wellington Management Group
10.02% · 4.98M sh
New Enterprise Associates, Inc.
7.28% · 3.61M sh
BlackRock
6.99% · 3.47M sh
OrbiMed Advisors LLC
6.19% · 3.07M sh
Paradigm Biocapital Advisors LP
5.05% · 2.51M sh
NVP Associates, LLC
4.30% · 2.14M sh
Deep Track Capital, LP
3.49% · 1.73M sh
Polar Capital Holdings Plc
3.24% · 1.61M sh
Vanguard Capital Management, LLC
3.49% · 1.68M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 19 sells
| Name | Role | Stake |
|---|---|---|
| Frazier Life Sciences Management, LP | -- | 13.40% |
| Wellington Management Group | -- | 10.02% |
| Peter Hawryluk | Former Officer | 2.45% |
| Richard Bartram | Former Chief Financial Officer | 0.10% |
| Ora Pescovitz | Independent Director | 0.05% |
| Steven Hoerter | Executive Chairperson, CEO & President | 0.04% |
| Salomon Azoulay | Chief Medical Officer | 0.00% |
| Patrick Heron | Independent Director | -- |
| OrbiMed Advisors LLC | -- | -- |
| James Cornelius | Former Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | Steven Hoerter | Executive Chairperson, CEO & President | Open Market Disposition | -4,893 | $54.82 |
| 2026-11-03 | Salomon Azoulay | Chief Medical Officer | Open Market Disposition | -373 | $53.96 |
| 2026-10-19 | Peter Radovich | -- | Other Derivative Acquisition | +18,200 | $53.50 |
| 2026-08-16 | Peter Hawryluk | Former Officer | Intent to Sell (Form 144) | -3,745 | $68.29 |
| 2026-08-03 | Peter Hawryluk | Former Officer | Intent to Sell (Form 144) | -936 | $65.77 |
| 2026-08-03 | Salomon Azoulay | Chief Medical Officer | Open Market Disposition | -370 | $65.77 |
| 2026-08-02 | John Smither | Chief Financial Officer | Other Acquisition | +28,000 | -- |
| 2026-08-02 | John Smither | Chief Financial Officer | Other Derivative Acquisition | +130,000 | $64.41 |
| 2026-08-02 | Steven Hoerter | Executive Chairperson, CEO & President | Other Acquisition | +71,000 | -- |
| 2026-08-02 | Steven Hoerter | Executive Chairperson, CEO & President | Other Derivative Acquisition | +331,000 | $64.41 |
| 2026-06-09 | Richard Bartram | Former Chief Financial Officer | Intent to Sell (Form 144) | -9,167 | $30.55 |
| 2026-06-08 | Richard Bartram | Former Chief Financial Officer | Intent to Sell (Form 144) | -10,833 | $29.66 |
| 2026-06-03 | Patrick Heron | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Edward Mathers | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Ora Pescovitz | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Tiba Aynechi | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Steven Ryder | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Steven Hoerter | Executive Chairperson, CEO & President | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Laurie Stelzer | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-05-12 | Richard Bartram | Former Chief Financial Officer | Intent to Sell (Form 144) | -15,000 | $36.95 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
MBX Biosciences discussion 0 comments